FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.

JACC. Advances2026PMID: 41576595

View on PubMed DOI: 10.1016/j.jacadv.2025.102575

Authors

Do, Duy; Murugiah, Karthik; Sawano, Mitsuaki; Goodwin Cartwright, Brianna M; Rodriguez, Patricia J; Gratzl, Samuel; Curtis, Lesley H; Jastreboff, Ania; Lu, Yuan; Stucky, Nicholas L

Keywords

GLP-1cardiovascular diseaseobesitysemaglutide